Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma

被引:18
|
作者
Zarei, Shabnam [1 ]
Wang, Yan [2 ]
Jenkins, Sarah M. [3 ]
Voss, Jesse S. [4 ]
Kerr, Sarah E. [5 ]
Bell, Debra A. [4 ]
机构
[1] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA
[2] Anhui Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Hefei, Peoples R China
[3] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Lab Med & Pathol, Hilton 11-30A,200 First St SW, Rochester, MN 55905 USA
[5] Hosp Pathol Associates, Minneapolis, MN USA
关键词
high-grade serous carcinoma; low-grade serous carcinoma; coexisting; sequencing; IHC; BRAF MUTATION; BORDERLINE TUMOR; STAGE; PATTERN; ERBB2;
D O I
10.1097/PAS.0000000000001419
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Despite the current classification of high-grade serous carcinoma (HGSCA) and low-grade serous carcinoma (LGSCA) as mutually exclusive diseases based on morphology and molecular pathogenesis, cases with mixed morphologic features of HGSCA and LGSCA have been reported. Herein we assess the clinicopathologic, immunohistochemical (IHC), and molecular genetic characteristics of a group of these cases, which we termed indeterminate grade serous carcinoma (IGSCA) in comparison with groups of HGSCA and LGSCA. Using the World Health Organization (WHO) classification criteria, we selected 27 LGSCA and 19 IGSCA for detailed morphologic study. Thirteen classic HGSCA, 19 classic LGSCA, and 19 IGSCA were selected for p53 and BRAF V600E IHC and molecular genetic testing by next-generation sequencing. IGSCA showed the architectural patterns of invasion of LGSCA, but with higher grade nuclear features focally and a mitotic index intermediate between LGSCA and HGSCA. Few cases in the IGSCA group showed mutant TP53 by IHC or sequencing (4/18, 22.2%), 1 case had mutant BRAF non-V600E by sequencing, and 1 had an NRAS mutation. When present, the mutations were identical in the low-grade and high-grade areas. The IGSCA group had a long-term survival similar to the classic HGSCA group. IGSCA with mixed morphologic features of HGSCA and LGSCA is a rare and potentially clinically aggressive variant of serous carcinoma. Their distinct morphologic, but heterogenous molecular features, including low frequency of TP53 and BRAF mutations suggest that these rare tumors may have a different pathogenesis pathway compared with classic HGSCA and classic LGSCA.
引用
收藏
页码:316 / 328
页数:13
相关论文
共 50 条
  • [11] Low-grade Serous Ovarian Carcinoma
    Ricciardi, Enzo
    Baert, Thais
    Ataseven, Beyhan
    Heitz, Florian
    Prader, Sonia
    Bommert, Mareike
    Schneider, Stephanie
    du Bois, Andreas
    Harter, Philipp
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (10) : 972 - 976
  • [12] Molecular Management of High-Grade Serous Ovarian Carcinoma
    Punzon-Jimenez, Paula
    Lago, Victor
    Domingo, Santiago
    Simon, Carlos
    Mas, Aymara
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [13] Molecular characteristics of low-grade serous carcinoma in effusions
    Doutel, Delfim
    Davidson, Ben
    Pettersen, Ina Kathrine Nitschke
    Torgunrud, Annette
    CYTOPATHOLOGY, 2023, 34 (02) : 99 - 105
  • [14] The "Far Left" of the Morphologic Spectrum of Ovarian High-grade Serous Carcinoma: Case Report of a Purely Noninvasive High-grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor
    Katsakhyan, Levon
    Baraban, Ezra G.
    Dumoff, Kimberly L.
    Burger, Robert A.
    Parikh, Rupal
    Cooper, Kumarasen
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2021, 40 (02) : 175 - 179
  • [15] Comprehensive molecular profiles of low-grade serous ovarian carcinoma
    ElNaggar, A. C.
    Robins, D. B.
    Arguello, D.
    Ulm, M. A.
    Mantia-Smaldone, G. M.
    Chu, C.
    Winer, I.
    Holloway, R. W.
    Krivak, T. C.
    Jones, N. L.
    Galvan-Turner, V.
    Herzog, T. J.
    Brown, J.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 60 - 61
  • [16] MIRNAS-LINKED TO ONCOGENES IN OVARIAN HIGH-GRADE VERSUS LOW-GRADE SEROUS CARCINOMA
    Schiff, S.
    Muinde, J.
    Carter, C.
    Khan, S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (01) : 471 - 471
  • [17] Integrated Molecular and Clinicopathologic Study of Tubo-Ovarian High-Grade Serous Carcinoma
    Santandrea, Giacomo
    Ceccarelli, Claudio
    Santini, Donatella
    Turchetti, Daniela
    Zamagni, Claudio
    Perrone, Anna Myriam
    De Iaco, Pierandrea
    De Leo, Antonio
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 744 - 744
  • [18] Integrated Molecular and Clinicopathologic Study of Tubo-Ovarian High-Grade Serous Carcinoma
    Santandrea, Giacomo
    Ceccarelli, Claudio
    Santini, Donatella
    Turchetti, Daniela
    Zamagni, Claudio
    Perrone, Anna Myriam
    De Iaco, Pierandrea
    De Leo, Antonio
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 744 - 744
  • [19] Transformation of ovarian low-grade serous carcinoma to high-grade carcinoma: a rare phenomenon and report of 4 cases
    Cai, E.
    Cheng, A. S.
    Gilks, B.
    Hoang, L. N.
    VIRCHOWS ARCHIV, 2018, 473 : S36 - S36
  • [20] High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour
    O'Neill, C. J.
    McBride, H. A.
    Connolly, L. E.
    Deavers, M. T.
    Malpica, A.
    McCluggage, W. G.
    HISTOPATHOLOGY, 2007, 50 (06) : 773 - 779